Boosted lopinavir-versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A Prospective study of HIV-infected individuals in high-income countries

Clinical Infectious Diseases

Volumn 60, Issue 8, 2015, Pages 1262-1268

  Cain, Lauren E ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

atazanavir; HIV; lopinavir; mortality; observational studies

Indexed keywords

ATAZANAVIR; LOPINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEATH; DEVELOPED COUNTRY; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES; ADOLESCENT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COOPERATION; HIV INFECTIONS; IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATAZANAVIR SULFATE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COOPERATIVE BEHAVIOR; DEVELOPED COUNTRIES; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 84926616670     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1167     Document Type: Article

References (21)

1. European AIDS Clinical Society. EACS guidelines, 2013. Available at: http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed 25 November 2013.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, 2014. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultand adolescentgl.pdf. Accessed 9 July 2014.
3. Writing G, Williams I, Churchill D, et al. British HIVAssociation guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013). HIV Med 2014; 15(suppl 1):1-85.
4. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410-25.
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013, 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng. pdf. Accessed 22 August 2014.
6. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-55.
7. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-32.
8. Andersson LM, Vesterbacka J, Blaxhult A, et al. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial. Scand J Infect Dis 2013; 45:543-51.
9. The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-37.
10. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
11. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162:199-200.
12. The HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012; 26:1691-705.
13. Cain LE, Hernan MA; on behalf of the HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Josep M. Llibre and Daniel Podzamczer and additional results. AIDS 2013; 27:2169-70.
14. The Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS 2013; 27:803-13.
15. Foglia E, Bonfanti P, Rizzardini G, et al. Cost-utility analysis of lopinavir/ ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS One 2013; 8:e57777.
16. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-72.
17. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavirbased once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23:1505-14.
18. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavirbased regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50:474-81.
19. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
20. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228-30.
21. Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio-or cerebrovascular disease events. AIDS 2013; 27:407-15.